Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
|Videos|October 7, 2014
The Impact of Angelina Jolie's Story on Genetic Referrals
Author(s)Jacques Raphael, MD
Jacques Raphael, MD, clinical fellow, Sunnybrook Odette Cancer Centre, discusses a study looking at the impact of Angelina Jolie’s decision and announcement to undergo a preventive double mastectomy.
Advertisement
Clinical Pearls
Jacques Raphael, MD, clinical fellow, Sunnybrook Odette Cancer Centre, discusses a study looking at the impact of Angelina Jolie’s decision and announcement to undergo a preventive double mastectomy.
- Researchers set out to determine the effect of the extensive media coverage of Angelina Jolie’s decision to undergo a preventive double mastectomy on the activity in a genetic clinic.
- Referrals increased from 487 to 916. Quality of referrals remained the same.
- The proportion of BRCA1/2 mutation carriers also remained the same.
Advertisement
Related to this article
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
4
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
5